DOCSLIB.ORG

395 B 536 Winstal. O. Saito EEEEEE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

USOO8426439B2 (12) UnitedO States Patent (10) Patent No.: US 8.426,439 B2 Ciccocioppo (45) Date of Patent: *Apr. 23, 2013 (54) COMPOSITIONS AND METHODS FOR 7,510,728 B2 3/2009 Koike ........................... 424/464 PROPHYLAXIS AND TREATMENT OF 7,517,900 B2 4/2009 Pendri et al. ... 514,404 7,524,975 B2 4/2009 Mae et al. ... 549,405 ADDCTIONS 2002fOOO6942 A1 1/2002 Davis ........... ... 514,369 2002fOO77320 A1 6/2002 Lohray et al. 514/226.2 (75) Inventor: Roberto Ciccocioppo, Camerino (IT) 2003/0069246 A1 4/2003 Darrow et al. ................ 514,245 2003/010.0587 A1 5/2003 Moinet et al. ................. 514,369 (73) Assignee: Omeros Corporation, Seattle, WA (US) 2003/0220373 Al 1 1/2003 Jaye et al. ... 514,342 2004/0028735 A1 2/2004 Kositprapa ... 424/468 2004/OO77525 A1 4/2004 Chapman et al. ... 514/2 - r 2004/0096499 A1 5/2004 Vaya et al. ... 424/468 (*) Notice: Subject to any disclaimer, the term of this 2004/0127443 A1 7/2004 Pershadsingh 514,44 patent is extended or adjusted under 35 2004/0204472 A1 10/2004 Briggs et al. 514,406 U.S.C. 154(b) by 859 days. 2005, 00041 79 A1 1/2005 Pedersen ...... ... 514,342 2005, OO14786 A1 1/2005 Sun et al. .. ... 514/313 This patent is Subject to a terminal dis- 2005, OO 14833 A1 1/2005 Clark et al. .. ... 514,561 claimer. 2005, 0096331 A1 5/2005 Das et al. 514,259.3 2005, 01711.1.0 A1 8, 2005 Yu et al. ....... ... 514,248 2006, OOO9518 A1 1/2006 Campbell et al. ... 514,522 (21) Appl. No.: 12/101,943 2006/0024365 A1 2/2006 Vaya et al. ... 424/468 (22) Filed: Apr. 11, 2008 2006/0059152 A1 3/2006 Nakamura ........................ 707/7 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS CA 2589 393 12/2007 US 2009/0048232A1 Feb. 19, 2009 EP 1867994 A2 12/2007 (Continued) Related U.S. Application Data OTHER PUBLICATIONS Cohen et al. CB1 receptor antagonists for the treatment of nicotine (60) Provisional application No. 60/911,201, filed on Apr. addiction. Pharmacology, Biochemistry and Behavior 81. 387-395 11, 2007. (2005).* Ang, E. et al., “Induction of nuclear factor-kappaB in nucleus (51) Int. Cl. accumbens by chronic cocaine administration.” J. of Neurochem. A6 IK3I/44 (2006.01) 79:221-224, 2001. (52) U.S. Cl. Asanuma, M. et al., “Methamphetamine-induced increase in USPC S14/293: 514/342: 514/811 striatalNF-kappaB DNA-binding activity is attenuated in Superoxide (58) Field of- -Classification - - - - - - - - - - - - - - - - - - - - - - - Search- - - ..................s s s1420s, dismutaseStase trrangenic ic mice,mice.” Molecular trainBrain researcR h 60:305-309, 514/342,811 Ashby, C. et al., “Acute Administration of the Selective D. Receptor See application file for complete search history. Antagonist SB-27701 1A Blocks the Acquisition and Expression of the Conditioned Place Preference Response to Heroin in Male Rats.” (56) References Cited Synapse 48:154-156, 2003. Continued U.S. PATENT DOCUMENTS ( ) 4,572,912 A 2/1986 Yoshioka et al. ............. so Primary Examiner - Barbara P Badio 4,582,839 A 4, 1986 Meguro et al. 514/342 Assistant Examiner — Sara E Townsley 4,687,777 A 8/1987 Meguro et al. 514,342 (74) Attorney, Agent, or Firm — Marcia S. Kelbon 4,725,610 A 2/1988 Meguro et al. 514,369 4,775,687. A 10/1988 Meguro et al. 514/369 (57) ABSTRACT 4,812,570 A 3/1989 Meguro et al. 546,280 The present invention relates to methods of treating or pre 5,965,584. A 10/1999 Ikeda et al. 514,342 venting addiction and relapse use of addictive agents, and g h '' A 58 With . SS treating or preventing addictive or compulsive behavior and k - W Cai Ca. 6,437,143395 B2B 5368/2002 MoinetWinstal. et al. ..O. ... Saito548, 183 EEEEEEg a p some p ited recept 6,506,762 B1 1/2003 Horvath et al. 514,2594 gamma (PPARy). agonist, alone or in combination with 6,582,738 B2 6/2003 Gubler .............................. 426, 5 another therapeutic agent, such as, for example, an opioid 6,620,830 B2 9/2003 Chiang .............. 514,369 receptor antagonist or an antidepressant. The present inven 6,794,154 B1 9/2004 Yamanouchi et al. 435/7.8 tion also includes pharmaceutical compositions for treating 7,037,910 B2 5/2006 Ewing et al. .................. 514,243 or preventing addiction or relapse that include a PPARYago 7,067,530 B2 6/2006 Jeppesen et al. ........... 514,311 nist and one or more other therapeutic agents, as well as unit 7,141,561 B2 11/2006 Schwinket al.......... 51421203 dosage forms of Such pharmaceutical compositions, which 7.312,229 B2 12/2007 Dankulich et al. ............ 514/284 contain a dosage effective in treating or preventing addiction 7,319, 170 B2 1/2008 Sahoo et al. ....... ... 564/43 1 Th thods and iti fthei ti 7,326,706 B2 2/2008 Ellsworth et al. .. 514,241 orrelapse. I nemeunoas and compositions oIune invention are 7,335,799 B2 2/2008 Dasseux et al. .... ... 568,861 useful in the treatment or prevention of addiction to any agent, 7,365,064 B2 4/2008 Bhuniya et al. 514,230.5 including alcohol, nicotine, marijuana, cocaine, and amphet 7,378.418 B2 5, 2008 Yu et al. ............. ... 514,248 amines, as well as compulsive and addictive behaviors, 7,381,736 B2 6/2008 Cheruvallath et al. ........ 514,370 including pathological gambling and pathological overeat 7,411,071 B2 8/2008 Yang et al. .................... 548,195 ing 7,429,575 B2 9, 2008 Yu et al. ......... 514,114 7,446,110 B2 11/2008 Kaufman et al. ............. 514,284 38 Claims, 25 Drawing Sheets US 8,426.439 B2 Page 2 U.S. PATENT DOCUMENTS WO WO 2007/039 125 4/2007 2006, OO84686 A1 4/2006 Barak ........................... 514,357 W. W. 3:29:25 5392 2006, O148721 A1 7/2006 Erondu. ................. ... 514/23 WO WO 2007/079239 7/2007 2006.0167045 A1 7/2006 Waldstreicher et al. 514,311 WO WO 2007/082206 7/2007 2006/0211749 A1 9, 2006 Bobotas et al. .... 514,369 WO WO 2007/083.146 7/2007 2006/0252670 A1 11/2006 Fiorucci et al. ................... 514/3 WO WO 2007/106862 9, 2007 2006/0270722 A1 1 1/2006 Thornberry et al. 514,374 WO WO 2007 120605 10/2007 2007/0O37882 A1 2/2007 Kita et al. .......... ... 514,548 WO WO 2007.121545 11, 2007 2007.0049576 A1* 3, 2007 Barlow et al. 514,214.03 WO WO 2007/126135 11, 2007 2007/004.9613 A1 3/2007 Chen et al. .. ... 514,290 WO WO 2007.1366O7 11, 2007 2007/0060547 A1 3/2007 Campbell et al. ... 514,64 WO WO 2008/OOO643 1, 2008 2007/0066630 A1 3/2007 Palani et al. ... 514,260.1 WO WO 2008/OO8433 1, 2008 2007.0099884 A1 5, 2007 Erondu et al. ... 514, 183 WO WO 2008/O13384 1, 2008 2007/01 12070 A1 5/2007 Aubert et al. ................. 514,534 WO WO 2008/O17398 2, 2008 2007/0167435 A1 7/2007 Mutahi et al. ................. 514,218 WO WO 2008/024284 2, 2008 2007/0167468 A1 7/2007 Schoenafinger et al. .. 514/263.2 WO WO 2008/024456 2, 2008 2007/O197606 A1 8/2007 Burczynski et al. .......... 514/342 WO WO 2008/030604 A2 3, 2008 2007/0213359 A1 9/2007 Burstein et al. ............... 514,300 WO WO 2008/030618 3, 2008 2007/0232573 A1 10, 2007 Patell et al. ................... 514,125 WO WO 2008/030651 3, 2008 2007/0238757 A1 10/2007 Chapman et al. 514,342 WO WO 2008/O5325.6 A1 5, 2008 2007/0276041 A1 11/2007 Oonuki et al. ... 514,563 WO WO 2008/063.842 5, 2008 2007,0299047 A1 12, 2007 Maher et al. 514,210.02 WO WO 2008/095263 8, 2008 2008, OO19978 A1 1/2008 Palani et al. ... 424,158.1 WO WO 2008/128126 10, 2008 2008, OO45580 A1 2/2008 Madhavan et all 514,378 WO WO 2008, 133884 11, 2008 2008, OO64671 A1 3/2008 Barlow et al. ................. 514,171 2008/0.103165 A1 5/2008 Barlow et al. ................. 514,297 OTHER PUBLICATIONS 2008/O127972 A1 6, 2008 Morton ....... 128,203.15 Barroso, I. et al., “Dominant negative mutations in human 2008, 0220078 A1 9/2008 Morton et al. ................ 424/490 PPARgamma associated with severe insulin resistance, diabetes mel 2010, O184806 A1 7, 2010 Barlow et al. litus and hypertension.” Nature 402:880-883, 1999. FOREIGN PATENT DOCUMENTS i s TMechanisms of Action of PPARs, Annu. Rev. JP 2008-44932 2, 2008 Bordet, R. et al., “PPAR: a new pharmacological target for KR 10-2007-01 12580 11, 2007 neuroprotection in stroke and neurodegenerative diseases. Bio W. W. 93. 1399. chemical Society 34(Pt6): 1341-1346, 2006. WO WO99.63983 12/1999 Bowers, M. et al., "Forebrain astroglial plasticity is induced follow ing withdrawal from repeated cocaine administration.” European W W 8.25 38: Journal of Neuroscience 17. 1273-1278, 2003. WO WO O2/49626 6, 2002 Breidert, T. et al., “Protective action of the peroxisome proliferator WO WO 03/026586 4/2003 activated receptor-gamma agonist pioglitaZone in a mouse model of WO WO 03/045918 6, 2003 Parkinson's disease.” Journal of Neurochemistry 82.615-624, 2002. WO WO 2004/OOO295 12/2003 Burstein, S., “PPAR-gamma: a nuclear receptor with affinity for WO WO 2004/O10992 2, 2004 cannabinoids.” Life Sciences 77:1674-1684, 2005. WO WO 2004/0781-13 9, 2004 Butcher, S. et al., “Neuroprotetive Actions of FK506 in WO WO 2004/0924.17 10, 2004 Experimentala Stroke: In Vivo evidence against an Antiexcitotoxic W.
Recommended publications
  • Summary of Product Characteristics

    Summary of Product Characteristics

    Package leaflet: Information for the patient Fluoxetine 20mg Capsules, hard fluoxetine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. •If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. What is in this leaflet 1. What Fluoxetine is and what it is used for 2. What you need to know before you take Fluoxetine 3. How to take Fluoxetine 4. Possible side effects 5. How to store Fluoxetine 6. Contents of the pack and other information 1. What Fluoxetine is and what it is used for The name of your medicine is Fluoxetine 20mg Capsules, hard. It contains the active substance fluoxetine. Fluoxetine belongs to a group of medicines called selective serotonin reuptake inhibitor (SSRI) antidepressants. Fluoxetine can be given to treat the following conditions: Adults: • Major depressive episodes • The symptoms of a condition called obsessive-compulsive disorder (OCD). • The eating disorder bulimia nervosa. This medicine is used alongside psychotherapy for the reduction of binge-eating and purging. Children and adolescents aged 8 years and above: • Moderate to severe major depressive disorder, if the depression does not respond to psychological therapy after 4-6 sessions. Fluoxetine should be offered to a child or young person with moderate to severe major depressive disorder only in combination with psychological therapy.
  • (PAC) Rev 24 Based on Applicable Aegls, Erpgs, Or Teels (Chemicals Listed by CASRN) PAC Rev 24 – August 2008

    (PAC) Rev 24 Based on Applicable Aegls, Erpgs, Or Teels (Chemicals Listed by CASRN) PAC Rev 24 – August 2008

    Table 3: Protective Action Criteria (PAC) Rev 24 based on applicable AEGLs, ERPGs, or TEELs (Chemicals listed By CASRN) PAC Rev 24 – August 2008 Table 3 presents a listing of chemicals and PAC data based on the Chemical Abstract Service Registry Numbers (CASRNs)1 of the chemicals. Chemicals without an identified CASRN number are issued an identification number, preceded by the letter “z,” for purposes of the PAC data set. The columns presented in Table 3 provide the following information: Heading Definition No. The ordered numbering of the chemicals as they appear in this listing by CASRN. Chemical Name The common name of the chemical. CASRN The Chemical Abstract Service Registry Number for this chemical. TEEL-0 This is the threshold concentration below which most people will experience no appreciable risk of health effects. This PAC is always based on TEEL-0 because AEGL-0 or ERPG-0 values do not exist. PAC-1 Based on the applicable AEGL-1, ERPG-1, or TEEL-1 value. PAC-2 Based on the applicable AEGL-2, ERPG-2, or TEEL-2 value. PAC-3 Based on the applicable AEGL-3, ERPG-3, or TEEL-3 value. Units The units for the PAC values (ppm or mg/m3). Additional information on the chemicals presented here is provided in PAC Tables 1, 2, and 4. Table 3, other PAC Tables, introductory/explanatory material (including a glossary of acronyms and abbreviations), definitions of PAC values, and alternative methods of displaying PAC information are available electronically at: http://www.hss.energy.gov/HealthSafety/WSHP/chem_safety/teel.html.
  • CDR Clinical Review Report for Soliqua

    CDR Clinical Review Report for Soliqua

    CADTH COMMON DRUG REVIEW Clinical Review Report Insulin glargine and lixisenatide injection (Soliqua) (Sanofi-Aventis) Indication: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units daily) alone or in combination with metformin. Service Line: CADTH Common Drug Review Version: Final (with redactions) Publication Date: January 2019 Report Length: 118 Pages Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document.
  • Comparison of Clinical Outcomes and Adverse Events Associated with Glucose-Lowering Drugs in Patients with Type 2 Diabetes: a Meta-Analysis

    Comparison of Clinical Outcomes and Adverse Events Associated with Glucose-Lowering Drugs in Patients with Type 2 Diabetes: a Meta-Analysis

    Online Supplementary Content Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. doi:10.1001/jama.2016.9400. eMethods. Summary of Statistical Analysis eTable 1. Search Strategies eTable 2. Description of Included Clinical Trials Evaluating Drug Classes Given as Monotherapy eTable 3. Description of Included Clinical Trials Evaluating Drug Classes Given as Dual Therapy Added to Metformin eTable 4. Description of Included Clinical Trials Evaluating Drug Classes Given as Triple Therapy When Added to Metformin Plus Sulfonylurea eTable 5. Risks of Bias in Clinical Trials Evaluating Drug Classes Given as Monotherapy eTable 6. Risks of Bias in Clinical Trials Evaluating Drug Classes Given as Dual Therapy Added to Metformin eTable 7. Risks of Bias in Clinical Trials Evaluating Drug Classes Given as Triple Therapy When Added to Metformin plus Sulfonylurea eTable 8. Estimated Global Inconsistency in Networks of Outcomes eTable 9. Estimated Heterogeneity in Networks eTable 10. Definitions of Treatment Failure Outcome eTable 11. Contributions of Direct Evidence to the Networks of Treatments eTable 12. Network Meta-analysis Estimates of Comparative Treatment Associations for Drug Classes Given as Monotherapy eTable 13. Network Meta-analysis Estimates of Comparative Treatment Associations for Drug Classes When Used in Dual Therapy (in Addition to Metformin) eTable 14. Network Meta-analysis Estimates of Comparative Treatment Effects for Drug Classes Given as Triple Therapy eTable 15. Meta-regression Analyses for Drug Classes Given as Monotherapy (Compared With Metformin) eTable 16. Subgroup Analyses of Individual Sulfonylurea Drugs (as Monotherapy) on Hypoglycemia eTable 17.
  • Modifications to the Harmonized Tariff Schedule of the United States To

    Modifications to the Harmonized Tariff Schedule of the United States To

    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
  • Comparative Safety and Effectiveness of Type 2 Diabetes Medicines Final Report September 2014

    Comparative Safety and Effectiveness of Type 2 Diabetes Medicines Final Report September 2014

    Type 2 Diabetes review – ToR 4 COMPARATIVE SAFETY AND EFFECTIVENESS OF TYPE 2 DIABETES MEDICINES FINAL REPORT SEPTEMBER 2014 A report by the Centre for Applied Health Economics (CAHE), Griffith University Type 2 Diabetes review – ToR 4 This report was commissioned by the Pharmaceutical Evaluation Branch, Department of Health, the Australian Government. Researchers: Erika Turkstra Senior research fellow, health technology assessment Martin Downes Research fellow, health technology assessment Emilie Bettington Senior research assistant Tracy Comans Senior research fellow, health technology assessment Paul Scuffham Professor and chair in health economics The assistance of Sanjeewa Kularatna with the data extraction and Gabor Mihala with the statistical analyses is appreciated. The advice provided by the Post-Market Review Section, Pharmaceutical Evaluation Branch, Department of Health and the Reference Group is also appreciated. Type 2 Diabetes review – ToR 4 CONTENTS ACRONYMS ............................................................................................................. III EXECUTIVE SUMMARY ............................................................................................ 1 PURPOSE OF THE REVIEW ........................................................................................... 1 BACKGROUND ............................................................................................................ 1 REVIEW OF CLINICAL GUIDELINES ...............................................................................
  • The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development

    The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development

    International Journal of Molecular Sciences Review The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development Fan Hong 1,2, Pengfei Xu 1,*,† and Yonggong Zhai 1,2,* 1 Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing 100875, China; [email protected] 2 Key Laboratory for Cell Proliferation and Regulation Biology of State Education Ministry, College of Life Sciences, Beijing Normal University, Beijing 100875, China * Correspondence: [email protected] (P.X.); [email protected] (Y.Z.); Tel.: +86-156-005-60991 (P.X.); +86-10-5880-6656 (Y.Z.) † Current address: Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15213, USA. Received: 22 June 2018; Accepted: 24 July 2018; Published: 27 July 2018 Abstract: Peroxisome proliferator-activated receptors (PPARs) are a well-known pharmacological target for the treatment of multiple diseases, including diabetes mellitus, dyslipidemia, cardiovascular diseases and even primary biliary cholangitis, gout, cancer, Alzheimer’s disease and ulcerative colitis. The three PPAR isoforms (α, β/δ and γ) have emerged as integrators of glucose and lipid metabolic signaling networks. Typically, PPARα is activated by fibrates, which are commonly used therapeutic agents in the treatment of dyslipidemia. The pharmacological activators of PPARγ include thiazolidinediones (TZDs), which are insulin sensitizers used in the treatment of type 2 diabetes mellitus (T2DM), despite some drawbacks. In this review, we summarize 84 types of PPAR synthetic ligands introduced to date for the treatment of metabolic and other diseases and provide a comprehensive analysis of the current applications and problems of these ligands in clinical drug discovery and development.
  • Official Protocol Title: NCT Number: NCT02750761

    Official Protocol Title: NCT Number: NCT02750761

    Official Protocol Title: A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to <12 Years Old NCT number: NCT02750761 Document Date: 23-Jun-2017 Tedizolid Phosphate (MK-1986) 1 Protocol TR701-120/MK-1986-013, Amendment 4 THIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., WHITEHOUSE STATION, NJ, U.S.A. SPONSOR: Cubist Pharmaceuticals, LLC, A wholly-owned indirect subsidiary of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the Sponsor or Merck) Weystrasse 20, Lucerne 6 Switzerland Protocol-specific Sponsor Contact information can be found in the Investigator Trial File Binder (or equivalent). TITLE: A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to <12 Years Old IND NUMBER: [106,307 (IV) and 125,076 (Oral Suspension)] EudraCT NUMBER: 2015-004595-29 23-Jun-2017 Confidential 04PPD9 Tedizolid Phosphate (MK-1986) 2 Protocol TR701-120, Amendment 4 SUMMARY OF CHANGES: TR701-120 Amendment 4 PRIMARY REASON(S) FOR THIS AMENDMENT: Section Change Rationale 1.0 Synopsis Updated dose for 6 to <12 years from 5 mg/kg to The dose level for the two age groups was adjusted Methodology; 4mg/kg, dose for 2 to <6 years from 5 mg/kg to 6 based on the results of the first interim analysis of the Investigational mg/kg based on the data from interim safety and safety and pharmacokinetic data.
  • Differential Inhibition of Neuronal and Extraneuronal Monoamine Oxidase Graeme Eisenhofer, Ph.D., Jacques W

    Differential Inhibition of Neuronal and Extraneuronal Monoamine Oxidase Graeme Eisenhofer, Ph.D., Jacques W

    Differential Inhibition of Neuronal and Extraneuronal Monoamine Oxidase Graeme Eisenhofer, Ph.D., Jacques W. M. Lenders, M.D., Ph.D., Judith Harvey-White, B.S., Monique Ernst, M.D., Ph.D., Alan Zametkin, M.O., Dennis L. Murphy, M.O., and Irwin J. Kopin, M.D. Tiiis study examined wlzetlzcr tile neuronal and 1-dcprcnyl tlzan with dcbrisoquin (255'¼, compared to a cxtmneuronal sites of action of two 1110110a111i11e oxidase 27% increase). Tlze comparable decreases in plasma (MAO) inlzibitors, 1-deprenyl and debrisoq11i11, could be concentrations of DHPG indicate a similar inhibition of disti11g11islzcd by their effects 011 plasma concentrations of intmncuronal MAO by both drugs. Much larger increases cateclw/a111ine metabolites. Plas111a co11centratio11s of tlzc in 110m1ct11nephrine after 1-deprenyl than after debrisoquin i11tra11euro11al dea111inatcd metabolite of" 11orepi11eplzrine, arc consistent with a site of action of the latter drug directed diiiydroxypiienylglycol WHPG), were decreased by 77'½, at the neuronal rather than the extraneuronal compartment. after debrisoquin and by 64'½, after l-dcpm1yl ad111i11istmtio11. Thus, differential changes in deaminated and O-methylated Plasma conccntmtions of the extmneuronal O-111etlzyl11tcd 11111i11c metabolites allm:us identification of neuronal and 111etabolitc of 11orcpineplzri11e, normctaneplzrine, were extra neuronal sites of action of MAO inhibitors. incrrnsed s11bst11ntiall11 more during treatment zpitfz [Neuropsychopharmacology 15:296-301, 1996] KEY IVORDS: Monoa111inc oxidase; Monomnine oxidase a family with an X-linked point mutation of the MAO-A inhibitors; Catec/10/11mi11es; Met11bolis111; Norcpincplzrine; gene where afflicted males exhibit impaired impulse Non11et1111cpl1ri11c control provides the most compelling evidence for a The monoamine oxidases (MAO) A and B catalyze the role of MAO in the expression of behavior (Brunner et deamination of biogenic amines and represent targets al.
  • Pharmaceuticals Compositions Comprising Sulphonylurea-Class Insulin Secretagogue and Polyethylene Glycol Castor Oil

    Pharmaceuticals Compositions Comprising Sulphonylurea-Class Insulin Secretagogue and Polyethylene Glycol Castor Oil

    (19) & (11) EP 2 438 911 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 11.04.2012 Bulletin 2012/15 A61K 9/20 (2006.01) A61K 31/4439 (2006.01) A61K 31/64 (2006.01) A61K 9/16 (2006.01) (21) Application number: 10013440.2 (22) Date of filing: 08.10.2010 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AL AT BE BG CH CY CZ DE DK EE ES FI FR GB yet been filed GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Hodzar, Damjan et al Designated Extension States: Lek Pharmaceuticals d.d. BA ME Verovskova 57 1526 Ljubljana (SI) (71) Applicant: LEK Pharmaceuticals d.d. 1526 Ljubljana (SI) (54) Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil (57) The present invention relates to the field of a rea-class insulin secretagogue active pharmaceutical in- pharmaceutical technology. More specifically, the gredient and at the same time, when both formulated into present invention relates to a pharmaceutical composi- a pharmaceutical composition, ensures satisfying or ex- tion comprising sulphonylurea-class insulin secreta- ceeding other parameters like for example stability, hard- gogue and a surface active agent. Surface active agent ness, friability and handling of said pharmaceutical com- obtainable by reacting castor oil or hydrogenated castor position. oil with ethylene oxide, preferably hydrogenated castor oil, substantially improves dissolution of the sulphonylu- EP 2 438 911 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 438 911 A1 Description Field of the invention 5 [0001] The present invention relates to the field of a pharmaceutical technology.
  • 2013 Pguy Acd Labs Presentation

    2013 Pguy Acd Labs Presentation

    ‘Next Generation Fingerprinting’ A GC‐HR‐TOF‐MS Method to Semi‐Quantify Constituents in Aerosols and Aerosol Fractions E. Dossin, A. Monge, E. Martin, P. Pospisil, A. Knorr, M.C. Bentley, P.A. Guy Metabolomics & Analytical Chemistry Gr., Philip Morris Products SA, 2000 Neuchatel, Switzerland Outline 1. Description of the existing GC-MS fingerprinting method Pros & cons of the current fingerprinting method Why switching to a 7200 Agilent high resolution MS instrument? 2. How to tackle semi-quantification of the smoke constituents with the help of chemoinformatics tools Curation step for smoke constituents to be monitored Analysis of reference standards Retention time prediction model (QSPR approach) Selection of appropriate internal standards (clustering approach) 3. Semi-quantification from calibration curve of reference standards Linearity Assessment of silylation 4. What about other smoke constituents? 5. Conclusion Page: 2 Existing Fingerprinting Method • Aerosol sample generated from a smoking machine (ISO) – Whole smoke – Gas Vapor Phase (GVP) sbPBS – Total Particulate Matter (TPM) • Compounds list • GC columns (HP6890 GC) – DB-624: HS-SPME-GC-MS Volatile Chemicals – DB-FFAP: GC-MS Non Polar Chemicals –DB-5-MS: HT-GC-MS Polar Chemicals (TMS) • Detection (MSD5973 MS) – Electron ionization mode – Full scan (low resolution) Semi-quantification (d6-phenol) Page: 3 Description of the Former GC‐MS Fingerprinting Method (HP6890 GC ‐ MSD5973 MS) Cell culture Medium plus Cigarette DB-624 column ● Headspace(HS)-SPME-GC-MS Smoke high
  • (12) United States Patent (10) Patent N0.: US 7,265,155 B2 Artman Et A1

    (12) United States Patent (10) Patent N0.: US 7,265,155 B2 Artman Et A1

    US007265155B2 (12) United States Patent (10) Patent N0.: US 7,265,155 B2 Artman et a1. (45) Date of Patent: *Sep. 4, 2007 (54) TREATING A VARIETY OF PATHOLOGICAL W0 98 08498 A 3/1998 CONDITIONS, INCLUDING SPASTICITY WO WO98/08498 3/1998 AND CONVULSIONS, BY EFFECTING A WO WO99/44623 3/1999 MODULATION OF CNS ACTIVITY WITH W0 WO 01/28516 10/2000 ISOVALERAMIDE, ISOVALERIC ACID, OR A RELATED COMPOUND OTHER PUBLICATIONS Schon and Blau, J Neurol Neurosurg Psychiatry, Sep. 1987: (75) Inventors: Linda D. Artman, Salt Lake City, UT 50(9):1148-1152.* (US); Manuel Balandrin, Sandy, UT Dorland’s Medical Dictionary 27th ed. p. 379* (US); Robert L. Smith, Lansdale, PA Pharmacotherapy, A Pathophysiologic Approach, Dipiro et al.2nd (Us) ed. 1991, pp. 1232, 1238).* Drug facts and comparisons 1999 ed. pp. 1595-1597(“Drug (73) Assignee: NBS Pharmaceuticals, Inc., Salt Lake Facts”).* City, UT (US) Pharmacotherapy, A Pathophysiologic Approach, Dipiro et al. 2nd ed. 1991, pp. 1232 & 1238* Notice: Subject to any disclaimer, the term of this Drug Facts and Comparisons. 1999 ed. pp. 1595-1597 (“Drug patent is extended or adjusted under 35 Facts”).* Julius A. Vida “Advances in Anticonvulsant Drug Development”; USC 154(b) by 0 days. Anticonvulsants (1997) pp. 1-9; Academic Press. Julius A. Vida “Noncyclic Anticonvulsants”; Anticonvulsants This patent is subject to a terminal dis (1977) pp. 577-619; Academic Press. claimer. Salim Hadad, et al. “Pharmacokinetic Analysis and Antiepileptic Activity of N-Valproyl Deriatives of GABA and Glycine”; Phar (21) Appl. N0.: 10/614,344 maceutical Research (1995), pp. 905-907; Plenum Publishing Cor poration.